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A B S T R A C T
The present guidelines on the management of extensive disease small cell lung can-
cer (SCLC) were formulated by the ELCWP in October 2007. They are designed to 
answer the following nine questions: 1) What is the definition of extensive disease? 2) 
What are the active drugs? 3) What is the best induction regimen? 4) Is there a role for 
maintenance chemotherapy? 5) Is there a role for dose-intensive chemotherapy? 6) Is 
there a role for the use of haemopoietic growth factors and stem cells support? 7) Is 
there a role for alternating or sequential chemotherapy? 8) Is there a role for biological 
treatments? 9) Is there a place for second-line chemotherapy?
I N T R O D U C T I O N
This is the fifth of a series of five articles, reporting clinical practice guidelines 
for lung cancer, formulated by the European Lung Cancer Working Party (ELCWP). 
These articles consecutively present the recommended treatment of early (resectable) 
stages of non-small cell lung cancer (NSCLC) (1), locoregionally advanced NSCLC 
(2), metastatic NSCLC (3) and small-cell lung cancer (SCLC) of limited and extensive 
stage. The rationale of the reasons and methodology used for those guidelines have 
been previously reported (1). After an extensive discussion, during a meeting organised 
in April 2007 in Brussels, Belgium, a consensus was reached among members of the 
Group to formulate the guidelines of treatment of extensive small cell lung cancer on 
the basis of nine predefined essential questions: 
1. What is the definition of extensive disease?
2. What are the active drugs? 
3. What is the best induction regimen? 
4. Is there a role for maintenance chemotherapy?
5. Is there a role for dose-intensive chemotherapy? 
6. Is there a role for the use of haemopoietic growth factors and stem cells sup-
port?
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7. Is there a role for alternating or sequential chemothera-
py? 
8. Is there a role for biological treatments? 
9. Is there a place for second-line chemotherapy?
These questions have been extensively discussed during the 
meeting of April 2007, in Brussels, Belgium. The consensus 
has been reached definitively approved by the Group in a final 
meeting in Valencia, Spain, in October 2007.
M E T H O D O L O G Y
Guidelines were established on the basis of published data: 
clinical trials, systematic reviews and meta-analyses, guidelines 
from medical societies or groups. Literature was identified and 
analysed by the evidence-based medicine group of the ELCWP. 
The quality of published guidelines was assessed using the 
AGREE instrument (4;5), allowing the elimination of the worst 
ones and the use of the best ones available in the formulation 
of our own guidelines. The following guidelines were selected: 
ASCO (American Society of Clinical Oncology) (6;7), BTS 
(British Thoracic Society) (8), Cancer Care Ontario Practice 
Guidelines (9;10), Royal College of Radiologists (RCR) (11), 
American College of Chest Physicians (ACCP) (12;13) and 
FNCLCC (Fédération Nationale des Centres de Lutte contre 
le Cancer) (14). Selection was based on the assessment of the 
literature previously performed by the ACCP (15) and it was 
completed by the analysis using the AGREE instrument of 
other guidelines not taken into consideration by the ACCP. 
This approach allowed adding to the list of guidelines those 
of FNCLCC and ACCP.
Concerning extensive disease small cell lung cancer specifi-
cally, guidelines were available only by Cancer Care Ontario, 
Royal College of Radiologists and ACCP. Recent evidence-
based recommendations have also been performed by the 
French review Prescrire (16).
Q U E S T I O N  1 :  W H A T  I S  T H E  D E F I N I T I O N 
O F  E X T E N S I V E  D I S E A S E ?
Two main systems can be used to define the extent of 
disease: the International Staging System (ISS) with TNM 
according to the last version published in 1997 by the UICC 
(17) or the two-stage system (limited or extensive disease) 
developed by the Veterans Administration Lung Cancer 
Study Group (VALCSG) (18). By definition, in any system, 
extensive disease is a disease which is not limited. In the 
VALCSG system, patients with limited disease (LD) have 
tumour involvement restricted to the ipsilateral hemithorax 
which can be included within a single radiation port. The 
International Association for the Study of Lung Cancer (19) 
also includes in the definition of limited disease the presence 
of contralateral hilar and/or ipsilateral and/or contralateral 
supraclavicular nodes and/or of pericardial and/or ipsilateral 
pleural effusion, regardless of the cytology.
In the published so far guidelines, the Royal College of 
Radiologists (11) defines limited disease as a disease con-
fined to one hemithorax, including involvement of ipsi-and/or 
contralateral hilar, mediastinal or supraclavicular node while 
ACCP (20) recommends the use of VALCSG definition. For 
the ELCWP, the disease should be staged according to both the 
ISS 97 and the VALCSG definitions. The definition of limited 
disease should be improved further, taking into account the 
tumour size and the volume that can be treated according to 
dose-volume histograms by the current radiotherapy techniques 
with a tolerable toxicity.
E L C W P  G U I D E L I N E S :
The disease should be staged according to both the ISS 
97 and the VALCSG definitions, as previously proposed in 
the ELCWP guidelines for limited disease small cell lung 
cancer.
Q U E S T I O N  2 :  
W H A T  A R E  T H E  A C T I V E  D R U G S ?
No available guidelines define the active drugs against 
SCLC. Thus, those that have been identified by experts on 
the basis of the available published trials in the literature, 
are considered active. They can be divided into three gen-
erations: the first generation comprises cyclophosphamide, 
etoposide, cisplatin, adriamycin, vincristine and methotrex-
ate; the second generation comprises ifosfamide, teniposide, 
carboplatin, epirubicin and vindesine; and the third generation 
comprises irinotecan, topotecan and paclitaxel. The activity of 
gemcitabine, docetaxel, vinorelbine and pemetrexed remains 
to be confirmed by randomised trials.
Second-generation drugs are mainly analogues of first-
generation drugs. Some have been tested in randomised 
trials: cisplatin versus carboplatin (21;22), etoposide versus 
teniposide (23), adriamycin versus epirubicin (24). In terms 
of activity and survival, newer drugs were found no advanta-
geous in any trial.
Several randomised trials aimed to determine the role of 
third-generation drugs in comparison to regimens using older 
drugs (table I). Almost all those studies failed to improve the 
results, no matter if paclitaxel (25-27), irinotecan (28;29) or 
topotecan (30) were tested.
E L C W P  G U I D E L I N E S :
Treatment should be based on the use of established active 
drugs. The active standard drugs of first and second genera-
tions are cyclophosphamide, etoposide, cisplatin, adriamycin, 
vincristine, methotrexate, ifosfamide, teniposide, carboplatin, 
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epirubicin and vindesine. The new active drugs are irinotecan, 
topotecan and paclitaxel.
Q U E S T I O N  3 :  W H A T  I S  
T H E  B E S T  I N D U C T I O N  R E G I M E N ?
The RCR (11) does not recommend any particular regimen 
among those that are most frequently used: PE (cisplatin + 
etoposide), CAV (cyclophosphamide + adriamycin + vincris-
tine), CDE (cyclophosphamide + adriamycin + etoposide). The 
ACCP (31) recommends a platinum-based chemotherapeutic 
regimen, with either etoposide or irinotecan (Simon II) and the 
evidence-based medicine review Prescrire (16) recommends 
the cisplatin plus etoposide combination.
The level of evidence is two meta-analyses. In the first 
one (32), the role of cisplatin and etoposide was assessed by a 
systematic review of the literature. Thirty-six trials were eligible 
for a total of 7,173 patients. Overall survival was significantly 
improved when etoposide was given (HR: 0.73; 95% CI: 0.67-
0.78; 17 trials), when cisplatin was added to etoposide (HR: 
0.74; 95% CI: 0.66-0.83; 9 trials) or when the cisplatin plus 
etoposide regimen was administered (HR: 0.57; 95% CI: 0.51-
0.64; 9 trials). In the second one (33), including 9 trials with 
1,579 evaluable patients, the addition of cisplatin significantly 
improved 6 month (OR: 0.87; 95% CI: 0.78-0.98) and 1 year 
(OR: 0.80; 95% CI: 0.69-0.93) survival rates.
It should be noted that there are only two published trials 
comparing cisplatin to carboplatin, one in association with 
etoposide (21) and the other with teniposide and vincristine 
(22). In both studies, there was no statistical difference between 
the arms in terms of response and survival.
The newer drugs have been so far unable to improve the 
survival results obtained with cisplatin plus etoposide (table I). 
The addition of paclitaxel to that combination failed to improve 
survival (25;27). Cisplatin plus topotecan (30) or irinotecan 
(29) were not better than cisplatin plus etoposide, despite a 
preliminary promising but unconfirmed trial (28).
E L C W P  G U I D E L I N E S : 
Cisplatin plus etoposide should be used as first-line in-
duction chemotherapy. Evidence is too limited to substitute 
carboplatin for cisplatin. Alternatively, if cisplatin can not be 
administered, the regimen should include etoposide.
Q U E S T I O N  4 :  I S  T H E R E  A  R O L E  
F O R  M A I N T E N A N C E  C H E M O T H E R A P Y ?
The RCR (11) recommends no maintenance treatment 
TABLE I. Randomised trials determining the role of third-generation active drugs in the first-line treatment of extensive 
small cell lung cancer.
Reference Population Arm N OR MS p
Mavroudis, 
2001 (25)
1st line, any stage CDDP 80 + NS
I. VP16 80x3 + paclitaxel 175 62 50% 9.5 m
II. VP16 120 x 3 71 48% 10.5 m
Noda, 
2002 (28)
1st line, ED I.CDDP 60 + irinotecan 60 x 3 77 85% 12.8 m 0.002
II. CDDP 80 + VP16 100 x 3 77 67% 9.4 m
Reck,
2003 (26)
1st line, any stage I. Carbo (AUC 5) + VP16 (125) + paclitaxel (175) 305 72% 12.7 m 0.024
II. Carbo (AUC 5) + VP16 (159) + VCR (2) 309 69% 11.7 m
Niell, 2005 (27) 1st line, ED CDDP (80 d1) + VP16 (80 d1-3) + NS
- 282 65 % 9.9 m
paclitaxel (175 J1) + GCSF 283 73 % 10.6 m
Eckardt,
2006 (30)
1st line, ED I. topotecan oral + cisplatin (60) 389 63 % 39.3 w NS
II. cisplatin (80) + etoposide 305 69 % 40.3 w
Hanna,
2006 (29)
1st line, ED I. irinotecan + cisplatin (30 x 2) 221 48 % 9.3 m NS
II. cisplatin (60) + etoposide 110 44 % 10.2 m
N: number; OR: objective response; MS: median survival; NS: non significant; m: month; w: week; ED: extensive disease; CDDP: cisplatin; carbo: 
carboplatin; VP16: etoposide
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and a maximum of 6 courses. For ACCP (34), maintenance 
chemotherapy has no indication outside the context of a 
clinical trial.
Level of evidence is based on 15 randomised trials (table 
II), a systematic review of the literature and a meta-analysis. 
In the systematic review performed by the ELCWP (35), 
randomised trials provided apparently contradictory results. 
In fact, there was a high heterogeneity between studies, both 
in their design (consolidation, maintenance or only further 
chemotherapy cycles; type of drugs used) and in their meth-
odology (such as lack of definition of the primary objective or 
of the a priori estimate of the sample size necessary to conduct 
the trial). It was concluded that a quantitative aggregation of 
such heterogeneous trials was meaningless. Nevertheless, the 
systematic review provides some indications in favour of the 
maintenance/consolidation chemotherapy such as for example 2 
cycles of cisplatin-etoposide after obtaining complete response 
with CAV or further cycles with that regimen when an objective 
response is obtained (35). The problem is that the majority of 
these studies were performed with regimens that are obsolete 
today. Nevertheless, a Turkish team performed a meta-analysis 
(36), showing significant 1-year (OR: 0.67; 95% CI: 0.56-0.79; 
14 trials) and 2-year (OR: 0.67; 95% CI: 0.53-0.89) survival 
improvement by maintenance treatment.
The two most recent trials showed significantly increased 
progression-free survival when oral topotecan (37) or oral 
etoposide (38) was given after 4 cycles of cisplatin-etoposide 
based chemotherapy.
E L C W P  G U I D E L I N E S : 
Maintenance chemotherapy trials gave conflicting results. 
So far, there is no indication for maintenance after induction 
by cisplatin plus etoposide. Chemotherapy should consist in 
at least 4 to 6 courses of induction chemotherapy in respond-
ing patients.
Q U E S T I O N 5 :  I S  T H E R E  A  R O L E  
F O R  D O S E - I N T E N S I V E  C H E M O T H E R A P Y 
( W I T H O U T  T H E  U S E  O F  H A E M O P O I E T I C 
G R O U T H  F A C T O R S ) ?
In their guidelines, the RCR (11) and the ACCP (39) both 
state that there is no role for dose-intensive chemotherapy in 
TABLE II. Randomised trials testing maintenance chemotherapy.
Reference Population  
randomised
CT induction N  
cycles
CT  
maintenance
N  
cycles
nb  
pts
PFS survival
Maurer, 1980 (58) CR CPA or CMV 6 cf induction until  
relapse
47 NS (S)
Cullen, 1986 (59) OR VAC 6 cf induction 8 61 ? (S)
Einhorn, 1988 (60) OR VAC 6 CDDP-VP16 2 151 S S
MRC, 1989 (61) OR VP16-CPA-MTX-VCR 6 cf induction 6 265 ? (S)
Spiro, 1989 (62) initial CPA-VCR-VP16 4 cf induction 4 610 S (S)
Byrne, 1989 (63) initial CDDP-VP16~CMV 3 x 2 CMV 6 66 NS NS
Ettinger, 1990 (47) CR VAC ± HMM-VP16-MTX 6-8 cf induction 20-22 86 (S) NS
Mattson, 1992 (64) OR CPA-VCR-VP16 + RT 4 CPA-CDDP-ADR 6 146 ? NS
Lebeau, 1992 (65) CR CCNU-CPA-ADR-VP16 6 cf induction 6 79 NS NS
Giaccone, 1993 (66) No progression ADR-VP16-CPA 5 cf induction 7 434 S NS
MRC, 1993 (67) initial VP16-CPA-MTX-VCR 3 cf induction 3 309 ? NS
Sculier, 1996 (68) OR Ifo-VP16-ADR or epir 6 VP16-VDS 12 91 S (S)
Beith, 1996 (69) OR CDDP-VP16 + RT 4 VAC 10 129 NS NS
Schiller, 2001 (37) OR & NC CDDP-VP16 4 Topotecan 4 223 S NS
Hanna, 2002 (38) OR & NC CDDP-VP16 - Ifo 4 oral VP16 3 144 S 0.07
N: number; OR: objective response; CR: complete response; PFS: progression-free survival; NS: non significant; S: significant; CT: chemotherapy; 
CDDP: cisplatin; VP16: etoposide; CPA: cyclophosphamide; Ifo: ifosfamide; ADR: adriamycin; VCR: vincristine; epir: epirubicin; MTX: 
methotrexate; HMM: hexamethylmelamine; RT: radiotherapy; CMC: CPA-MTX-VCR; VAC: CPA-ADR-VCR
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TABLE III-A. Randomised clinical trials testing the increase in the number of active drugs in the combination.
Reference Chemotherapy stage n pts OR p MS p
Edmonson, 
1976 (70)
1. CPA
2. + CCNU
all 118
110
22%
43%
NA 17.1 w
11.7 w
NA
Hansen,
1978 (71)
1. CCNU-CPA-MTX
2. + VCR
ED 52
53
75%
78%
NS 176 d
230 d
S
Maurer, 
1980 (58)
1. CPA-MTX
2. + VCR
LD
ED
LD
ED
41
40
47
33
51%
23%
62%
36%
NA 9.0m
5.3m
9.3m
5.7m
NS
Ettinger, 
1982 (72)
1. CCNU-CPA
2. + PCZ
all 97
95
28%
46%
NA 21 w
27 w
NS
Jackson, 
1984 (73)
1. CPA-ADR-VCR
2. + VP16
all 67
68
64%
86%
S 9.5m
10.6m
NS
Lowenbraun, 
1984 (74)
1. CPA-ADR-VCR
2. + VP16
ED 148
145
72%
74%
NS 42.1 w
42.3 w
NS
Zhiyi, 
1984 (75)
1. CPA-ADR-5FU
2. + PCZ
all 19
19
68 w
68 w
NS
Messeih, 
1987 (76)
1. CPA-ADR-VCR
2. + VP16
all 49
43
50%
65%
NS 36 w
45 w
NS
Jackson, 
1988 (77)
1. CPA-ADR-VCR
2. + VP16
ED 68
71
46% 
70%
S 7.8m
9.4m
NS
Niiranen, 
1989 (78)
1. CPA-VCR
2. + MTX-CCNU
LD 29
26
46%
56%
NS 12m
16m
NS
Jett, 
1990 (79)
1. CPA-ADR-VCR
2. + VP16
LD 113
118
83% 
84%
NS 12.4m
15.1m
NS
Sculier, 
1990 (80)
1. VP16-VDS
2. + CDDP
all 106
95
55%
74%
S 40 w
45 w
NS
Nikkanen, 
1990 (81)
1. CPA-ADR-VCR
2. + VP16
LD 41
39
84%
75%
NS 10 m
14 m
NS
Smith,
1991 (82)
1. VCR-ADR-CPA-VP16
2. + CDDP
all 48
47
65% 
72%
NS 47 w
40 w
NS
Miyamoto, 
1992 (83)
1. CDDP-VP16
2. + Ifo 
All 45
47
78% 
74%
NS 55 w
56 w
NS
N: number; OR: objective response; MS: median survival; NA: non available; NS: non significant; m: month; w: week; d: days; ED: extensive disease; 
LD: limited disease; NS: non significant; S: significant; CT: chemotherapy; CDDP: cisplatin; carbo or CBDCA: carboplatin; VP16: etoposide; 
CPA: cyclophosphamide; Ifo: ifosfamide; ADR: adriamycin; VCR: vincristine; VDS: vindesine; 5FU: 5-fluorouracil; MTX: methotrexate; PCZ: 
procarbazine; PAC: paclitaxel 
the management of SCLC.
The level of evidence is derived from randomised clinical 
trials testing various modalities to provide more intensive 
chemotherapy: increase of the number of active drugs in the 
combination, increase of the dose of one or more administered 
drugs, weekly chemotherapy administration, increased relative 
dose-intensity (RDI) for a same total cumulative dose (dose-
dense or concentrated chemotherapy), use of haemopoietic 
growth factors (see question 7).
The effect of the addition of one or two drugs to a basic 
combination (table III) has been tested in 23 randomised 
trials. Only 4 have shown a benefit in terms of survival and 
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5 in terms of response rate. In fact, most studies are biased 
because drug doses have been reduced in the regimen when 
a new drug was added. The impact of drug dose augmenta-
tion in a given combination (table IV) has been tested in 8 
randomised trials, all presenting methodological problems 
or using parallel endpoints. Weekly chemotherapy (table V) 
has been investigated in 6 randomised trials, without show-
ing significant advantage in terms of survival and response. 
Often, weekly chemotherapy was associated with a diminu-
tion of dose-intensity. Dose-dense chemotherapy (table VI), 
providing an increased RDI for a same total cumulative dose, 
has been tested in two randomised trials, including one with 
deleterious effect (40).
Dose-intensive chemotherapy can also be provided with 
the use of haemopoietic growth factors. That aspect will be 
discussed in the next question.
E L C W P  G U I D E L I N E S :
There is no evidence in favour of dose-intensive chemo-
therapy, whatever the modality.
Q U E S T I O N  6 :  I S  T H E R E  A  R O L E  F O R 
T H E  U S E  O F  H A E M O P O I E T I C  G R O W T H 
F A C T O R S  A N D  S T E M  C E L L S  S U P P O R T ?
The only guideline on the topic, made by the ACCP (41), 
does not recommend the routine use of G-CSF.
The level of evidence is derived from multiple randomised 
clinical trials and a meta-analysis. Haemopoietic growth 
factors can be used for four purposes: maintenance of dose-
intensity through neutropenia diminution, acceleration of 
chemotherapy, administration of dose-dense chemotherapy 
(concentration) and use of megadose chemotherapy (with 
stem cells support).
For the maintenance of dose-intensity, the evidence comes 
from secondary endpoint analyses of randomised trials per-
formed in order to reduce neutropenia and thus to diminish 
TABLE III-B. Randomised clinical trials testing the increase in the number of active drugs in the combination.
Reference Chemotherapy Stage n pts OR p MS p
Gatzemeier, 
1994 (84)
1. VP16-VCR
2. + CBDCA
ED 173
171
60%
80%
S 9 m
10 m
NS
Loehrer, 
1995 (85)
1. CDDP-VP16
2. + Ifo
ED 84
87
67%
73%
NS 7.3 m
9.1 m
S
MRC, 
1996 (86)
1. VP16-VCR
2. + CPA-MTX
All 156
154
46%
40%
NS 137 d
141 d
NS
Urban, 
1999 (49)
1. CPA-ADR-VP16
2. + CDDP
all 228
229
52%
72%
S 266 d
271 d
NS
Hirsch,
2001 (87)
1. Carbo + CDDP + VM26 + 
VCR then CPA + epirubicin 
2. Idem without CDDP 
all
LD
ED
all
LD
ED
140
67
68
149
74
60
71
78
67
72
69
75
314 d
417 d
232 d
294 d
327d
233 d
S
NS
Pujol,
2001 (88)
1. CDDP-VP16
2. Idem + CPA-epirubicine
ED 109
117
61
76
NS 9.3 m
10.8 m
0.006
Mavroudis, 
2001 (25)
CDDP 80 +
I. VP16 80x3 + PAC 175
II. VP16 120 x 3
all
62
71
50%
48%
9.5 m
10.5 m
NS
De Marinis,
2005 (89)
CDDP + gemcitabine
1. -
2. + VP16
ED
70
70
57%
63%
NS 10m
9.5m
NS
N: number; OR: objective response; MS: median survival; NA: non available; NS: non significant; m: month; w: week; d: days; ED: extensive disease; 
LD: limited disease; NS: non significant; S: significant; CT: chemotherapy; CDDP: cisplatin; carbo or CBDCA: carboplatin; VP16: etoposide; 
CPA: cyclophosphamide; Ifo: ifosfamide; ADR: adriamycin; VCR: vincristine; VDS: vindesine; 5FU: 5-fluorouracil; MTX: methotrexate; PCZ: 
procarbazine; PAC: paclitaxel 
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the risk of infectious complications (table VII). Those trials 
failed to show significant effect on response rate and survival, 
despite better delivered dose-intensity with the growth factors. 
The results have been confirmed by an ad hoc meta-analysis 
of the literature (42) with a survival HR of 1.004 (95% CI: 
0.89-1.13). 
Accelerated chemotherapy (table VIII) has also failed 
to improve survival in all but one trials. The meta-analysis 
did not show a significant effect (42). As mentioned above, 
dose-dense (concentration) chemotherapy, with the purpose 
to increase RDI for a same total cumulative dose, failed to 
improve results (table VI). There was even a deleterious trial 
(40). Megadose chemotherapy with the support of blood-pro-
genitors-cell support has been the topic of two randomised 
trials (table IX), one as late consolidation (43) and another 
as induction chemotherapy (44). That modality failed also to 
improve results.
E L C W P  G U I D E L I N E S : 
There is no evidence for improved survival by using hae-
mopoietic growth factors or stem cells support to increase or 
to maintain dose-intensity, whatever the proposed modality. 
Q U E S T I O N  7 :  I S  T H E R E  A  R O L E  
F O R  A L T E R N A T I N G  O R  S E Q U E N T I A L 
C H E M O T H E R A P Y ?
Alternating chemotherapy consists in cycles of two che-
motherapy regimens A and B in the following way ABABAB 
while sequential chemotherapy provides them successively as 
AAABBB. That concept has been investigated in multiple 
randomised clinical trials summarised in table X. When bet-
ter results were obtained, they can easily be explained by the 
use of better drugs in the improved arm, such as cisplatin and 
etoposide (45-49).
TABLE IV. Randomised clinical trials testing drug dose increase 
Reference Chemotherapy with dosage (mg/m²) Stage nb pts OR p MS p
Cohen,
1977 (90)
CCNU-MTX- CPA
1. 100 15 1000
2. 50 10 500
all
23
9
96%
45%
NA NA
Figueredo, 
1985 (91)
ADR-VCR-CPA
1. 60 1 1500-2000
2. 50 1 1000
all
52
51
71%
61%
NS NS
O’Donnell, 
1985 (92)
CPA- VCR- meCCNU
1. 2000 2 100
2. 750 2 75
all
14
14
43%
72%
NS
43 w
36 w
NS
Wolf,
1986 (93)
VP16 J1-3
1. 100
2. 200
3. 300
All pretreated
26
27
26
4%
7%
4%
NS
12.6 w
20.0 w
22.5 w
NS
Johnson,
1987(94)
CPA-ADR-VCR
1. 1200 70 1
2. 1000 40 1
ED
101
146
64%
53%
S
29.3 w
34.7 w
NS
Arriagada, 
1993 (95)
CPA-CDDP-ADR-VP16 (!1st course only)
1. 1200 100 40 225
2. 900 80 40 225
LD
51
48
(CR)
67%
54%
NS 2 yrs
43%
26%
S
Ihde,
1994 (96)
CDDP – VP16
1. 135 400
2. 80 240
ED
44
46
86%
83%
NS
11 m
10 m
NS
Pujol,
1997(40)
CPA-Epir-VP16-CDDP
1. 1800 60 330 120
2. 1200 40 225 100
ED
65
60
87%
74%
NS
8.9 m
11 m
S
N: number; OR: objective response; CR: complete response; MS: median survival; NA: non available; NS: non significant; m: month; w: week; yr: 
year; ED: extensive disease; LD: limited disease; NS: non significant; S: significant; CDDP: cisplatin; VP16: etoposide; CPA: cyclophosphamide; 
ADR: adriamycin; VCR: vincristine; MTX: methotrexate; epir: epirubicine. 
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E L C W P  G U I D E L I N E S :
There is no evidence in favour of the use of alternating or 
sequential chemotherapy.
Q U E S T I O N  8 :  I S  T H E R E  A  R O L E  
F O R  B I O L O G I C A L  T R E A T M E N T ?
Randomised clinical trials have tested interferons, antico-
agulants/antiaggregatants and metalloproteinase inhibitors.
Interferons, either administered as maintenance or as 
induction together with chemotherapy, have failed to provide 
better results (table XI). In addition, they were associated 
with significant toxicity.
Anticoagulants (heparin, warfarin) and antiaggregatants 
(aspirin) (table XII) have been associated with potentially 
TABLE V. Randomised clinical trials testing weekly chemotherapy
Reference Chemotherapy Stage nb pts OR p MS p RDI
Sculier,
1993 (97)
1. ADR-VP16-CPA~ CDDP-VDS~MTX-VCR
2. ADR-CPA-VP16
all 107
108
69%
61%
NS 49 w
43 w
NS 71%
85%
Souhami, 
1994 (98)
1.CDDP-VP16~Ifo-ADR
2.CDDP-VP16~VAC
all 221
217
82%
81%
NS 11 m
11 m
NS 73%
93%
James, 
1996 (99)
1.CDDP-VP16~VAC
2.CDDP-VP16~VAC
all 78
89
59%
45%
NS 6 m
6 m
NS 87%
90%
Furuse,
1998 (100) 
1.CDDP-VP16~VAC
2.CODE + G-CSF (CDDP-ADR-VP16-VCR)
ED 113
114
76%
85%
NS 11 m
12 m
NS 82%
72%
Murray, 
1999 (101) 
1. CODE
2. CAV ~ CDDP-VP16
ED 110
109
87%
70%
S 0.98 yr
0.91 yr
NS
Sekine,
2003 (102)
CDDP-VP16-Irinotecan
1.weekly
2.monthly
ED
30
30
80%
67%
8.9 m
12.9 m
N: number; OR: objective response; RDI: relative dose-intensity; MS: median survival; NS: non significant; m: month; w: week; yr: year; ED: 
extensive disease; NS: non significant; S: significant;; CDDP: cisplatin; VP16: etoposide; CPA: cyclophosphamide; ADR: adriamycin; VCR: 
vincristine; MTX: methotrexate;; Ifo: ifosfamide; VAC: CPA-ADR-VCR; CODE: CDDP + VCR + ADR + VP16
TABLE VI. Randomised clinical trials testing dose-dense or concentration chemotherapy.
Reference Chemotherapy (mg/m²) Stage nb pts OR p MS p
Pujol,
1997 (40)
CPA-Epir-VP16-CDDP ED NS S
1. 1800 60 330 120 + GM 65 87% 8.9 m
2. 1200 40 225 100 60 74% 11 m
Ardizzoni,
2002(103)
CPA-ADR-VP16 any NS NS
1. 1 45 300 119 79% 54 w
2. 1,2 55 375 + G 125 84% 52 w
N: number; OR: objective response; MS: median survival; NS: non significant; m: month; w: week; ED: extensive disease; NS: non significant; S: 
significant; CDDP: cisplatin; VP16: etoposide; CPA: cyclophosphamide; ADR: adriamycin; Epir: epirubicine
interesting results in a trial with heparin given during the first 
5 weeks of induction chemotherapy (50).
Marimastat, a metalloproteinase inhibitor, given as con-
solidation after remission obtained by chemotherapy, has failed 
to improve survival (51).
E L C W P  G U I D E L I N E S :
There is no evidence in favour of the use of biological 
treatments for routine application. Anticoagulants merit 
further investigations.
Q U E S T I O N  9 :  I S  T H E R E  A  P L A C E  F O R 
S E C O N D  L I N E  C H E M O T H E R A P Y ?
For ACCP (52), the second-line chemotherapy will depend 
on the lack of response to first-line chemotherapy (sensitive 
HOSPITAL CHRONICLES 2(3), 2007
126
relapse versus refractory patients) or on the response duration 
after first-line chemotherapy. For the Ontario Cancer Care 
Programme (53), the selection of patients should be depen-
dent on the treatment-free interval, the extent of response to 
first-line chemotherapy, the residual toxicity from first-line 
chemotherapy and the performance status of the patient. There 
is insufficient evidence to recommend a specific chemotherapy 
regimen. According to Prescrire (16), there is no particular 
second-line chemotherapy regimen to be recommended.
There is only one randomised clinical trial comparing 
supportive care only with chemotherapy using single-agent 
oral topotecan (54). Survival was significantly improved with 
active treatment (Table XIII). In another trial (55), that drug 
was no better than the VAC regimen (vincristine + adriamycin 
+ cyclophosphamide). Two other small randomised trials are 
also available for salvage chemotherapy (56;57).
E L C W P  G U I D E L I N E S :
Second-line chemotherapy is associated with a small im-
provement in survival. If relapse occurs after a response to 
the first-line chemotherapy with a chemotherapy-free interval 
of more than 3 months, the tumour can be considered still 
sensitive. In the other situations, the only active combination 
is cisplatin-etoposide for patients with no prior exposure to 
these drugs. No other chemotherapy regimen can be specifi-
cally recommended.
TABLE VII. Randomised clinical trials testing the main-
tenance of dose-intensity with the use of haematopoietic 
growth factors.
Reference Regimen N pts OR p MS p
Crawford, 
1991(104)
ACE 199 80%
NS
12 m
NSIdem + G 72% 11 m
Trillet, 1993 
(105;106)
ACE 130 87%
NS
12 m
0.27Idem + G 79% 11 m
Hamm, 
1994 (107)
ACE 233 86%
NS 0.8Idem + GM 75%
Bunn, 
1995 (108)
CDDP-VP16 230 86%
NS
17 m
0.15Idem + GM 73% 14 m
Steward, 
1998 (109)
VICE 98 77% NS
Idem + GM 78%
Fukuoka, 
1997 (110)
CODE 63 84%
0.07
8 m
0.004Idem + G 97% 15 m
Gatzemeier, 
2000 (111)
ACE 280 79%
NS
10 m
NSIdem + G 76% 11 m
N: number; OR: objective response; MS: median survival; NS: non 
significant; m: month; NS: non significant; CDDP: cisplatin; VP16: 
etoposide; CPA: cyclophosphamide; ADR: adriamycin; VCR: 
vincristine; CODE: CDDP + VCR + ADR + VP16; ACE: CPA + 
ADR + VP16; G: G-CSF; GM: GM-CSF; VICE: VCR + ifosfamide 
+ CDDP + VP16
TABLE VIII. Randomised clinical trials testing accelerated chemotherapy.
Reference chemotherapy stage n pts OR % p MS p RDI % p
Miles,
1994 (112)
CDDP-VP16~Ifo-ADR
all NS NS1. accelerated-CSF 23 74 ? 84
2. accelerated 17 71 ? 82
Woll,
1995 (113)
VCR-Ifo-CBDCA-VP16
all NS NS S1. accelerated +G-CSF 34 94 69 w 134
2. accelerated 31 93 64 w 117
Steward,
1998 (109)
CBDCA-VP16-Ifo-VCR
all NS S ND1. accelerated +/- GM-CSF(q3 wks) 147 90 443 d 126
2. non accelerated +/- GM-CSF (q4wks) 153 77 351 d 100
Thatcher,
2000 (114)
CPA – ADR – VP16
all NS 0.041. q2wks + G-CSF 201 79 95
2. q3wks 202 78 85
Woll,
2001 (115)
Ifo + Carbo + VP16
all 50 NS 0.891. standard 76 12 m
2. accelerated + G-CSF 80 12 m
Sculier,
2001 (116)
Ifo + VDS + epirubicine
ED 0.04 0.86 <0.001
1. standard 78 59 286 d 93
2. accelerated + GM-CSF 78 76 264 d 90
3. accelerated+ cotrimoxazole 77 70 264 d 65
N: number; OR: objective response; RDI: relative dose-intensity; MS: median survival; NS: non significant; m: month; w: week ED: extensive 
disease; NS: non significant; S: significant;; CDDP: cisplatin; VP16: etoposide; CPA: cyclophosphamide; ADR: adriamycin; VCR: vincristine; Ifo: 
ifosfamide; VDS: vindιsine; CBDCA or carbo: carboplatine
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TABLE X. Randomised clinical trials testing alternating or sequential chemotherapy.
Reference chemotherapy arm stage nb pts OR % MS p
Chak, 
1982 (117)
A: PCZ-VCR-CPA-CCNU
B: VP16-ADR-MTX
A
all
85
NS
B~A 76
Osterlind,  
1983 (118)
A: BCNU-CPA-VCR-MTX
B: ADR-VP16
A
ED
76 68 36 w
NSA~B 70 72 38 w
Daniels,
1984 (119)
A: CPA-VCR-PCZ-CCNU
B: VP16-ADR-MTX
A
all
84 53
NS
A~B 78 63
Livingston,  
1984 (120)
A: VCR-MTX-VP16
B: VAC
A
ED
146 58 28 w
NSB 155 60 31 w
A~B 144 64 33 w
Maurer, 
1985 (121)
A: MTX-ADR-CPA-CCNU
B: CCNU-CPA-VCR
C: ADR-VCR
A
LD
157 74 12m
NSB~C 150 72 12m
Havemann
1987 (45)
A: CCNU-ADR-VCR
B:VP16-VDS-Ifo
C:CPA-MTX-CCNU
A
all
152 59 10m
SA~B~C 150 70 11m
Evans, 
1987 (46)
A: VAC
B: CDDP-VP16
A
ED
144 63 8m
S
A~B 145 80 10m
Feld,
1987 (122)
A: VAC
B:CDDP-VP16
A~B
LD
154 82 62w
NS
3A3B 146 77 60w
Chahinian,
1989 (123)
A: MTX-ADR-CPA-CCNU
B: MMC-VP16-CDDP-HMM
A
ED
86 51 8m
NS
A~B 105 48 8m
Havemann,
1989 (124)
A: Ifo-VP16
B: VAC
A
all
161 75 10m
NS
A~B 165 59 10m
Goodman,
1990 (125)
A: VP16-CPA-ADR-VCR
B: CDDP-VP16
C: VAC
A
LD
199 68 15m
NSB~C 201 72 17m
Ettinger, 
1990 (47)
A: VAC
B: HMM-VP16-MTX
A
ED
294 61 43w
S
A~B 283 64 46w
Fukuoka, 
1991 (48)
A: VAC
B: CDDP-VP16
A
all
97 55 10m
(S)B 97 78 10m
A~B 94 76 12m
Wolf,
1991 (126)
A: Ifo-VP16
B: VAC
A
all
162 77 11m
NS
A~B 159 70 10m
Wampler,
1991 (127)
A: VAC
B: MTX-CDDP-VP16
A
ED
79 54 7m
NS
B~A 82 53 9m
Roth,
1992 (128)
A: CDDP-VP16
B: VAC
A
ED
148 61 9m
NSB 146 51 8m
A~B 143 60 8m
Joss,
1994 (129)
A: ADR-CDDP-VP16
B: CPA-VP16-ADR
C: MTX-VCR-CPA
A
all
92 80 319d
NSB 86 56 265d
C~A 88 88 288d
Joss,
1995 (130)
A: CDDP-ADR-VP16
B: CPA-MTX-VCR-CCNU
A~B
tall
202 88 339d
(S)
3A3B 204 87 371d
Postmus,
1996 (131)
A: CPA-ADR-VP16
B: VCR-CBDCA-Ifo
A
ED
75 68 8m
NS
A~B 73 70 9m
Urban, 
1999 (49)
A: CCNU-CPA-ADR-VP16
B: CCNU-ADR ~CDDP-VDS-VP16
A x 6
all
223 78 306d
0.08
B 3x2 191 64 272 d
N: number; OR: objective response; MS: median survival; S: significant; NS: non significant; m: month; w: week; d: days; ED: extensive disease; LD: 
limited disease; CDDP: cisplatin; carbo or CBDCA: carboplatin; VP16: etoposide; CPA: cyclophosphamide; Ifo: ifosfamide; ADR: adriamycin; VCR: 
vincristine; VDS: vindesine; MMC: mitomycin C; HMM: hexamethylmelamine; MTX: methotrexate; PCZ: procarbazine; VAC: CPA-ADR-VCR.
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TABLE IX. Randomised clinical trials testing megadosage chemotherapy
Reference chemotherapy nb pts OR % p MS p
Humblet, 1987(43) 1. Standard 22 55 w NS
2. Late intensification with autoBMT 23 68 w
Lorigan, 2005 (44) 1. Standard: Ifo (5) – Carbo (300) – VP16 (180 x 2) q4 wks 159 88% 0.09 13.9 m NS
2. Intensified: Ifo (5) – Carbo (300) – VP16 (180 x 2) q2 wks  
with filgrastine and PBCs
159 89% 14.4 m
N: number; OR: objective response; MS: median survival; NS: non significant; m: month; w: week NS: non significant; BMT: bone marrow 
transplantation; VP16: etoposide; carbo: carboplatine; PBC: progenitor blood cell
TABLE XI. Randomised clinical trials testing interferons.
Reference chemotherapy IFN modality stage nb pts MS CT MS CT + IFN p
Mattson, 1992 (64) CPA-VCR-VP16  6 m maintenance all 237 11m 11m NS
Jett, 1994 (132) CDDP-VP16  6 m maintenance CR all 100 19m 13m NS
Kelly, 1995 (133) CDDP-VP16 + RT  2 yrs maintenance OR LD 133 10m 9m NS
Zarogoulidis, 1996 (134) CBDCA-Ifo-VP16 
CT
induction
6-8 m
all 45 11m 10m NS
van Zandwijk
1997 (135)
various 
4 m
maintenance
CR
all 120 10m 9m NS
Prior,
1997 (136)
VAC~CDDP-VP16 
6 m
induction
6 m
all 77 9m 11m 0.02
Ruotsalainen,
1999 (137)
CDDP-VP16 I.  RC
II.  Roche
induction all 219 10 m 10 m
10 m
NS
N: number; OR: objective response; CR: complete response; CT: chemotherapy; IFN: interferon; MS: median survival; NS: non significant; m: 
month; yr: year; LD: limited disease; CDDP: cisplatin; CBDCA: carboplatin; VP16: etoposide; CPA: cyclophosphamide; Ifo: ifosfamide; ADR: 
adriamycin; VCR: vincristine; VAC: CPA-ADR-VCR.
TABLE XII. Randomised clinical trials testing anticoagulants/antiaggregatants
Reference chemotherapy anticoagulant/  
antiaggregant
modality stage nb pts MS CT MS CT 
+ anti
p
Chahinian, 1989 (123) MTX-ADR-CPA-CCNU warfarine induction ED 189 8m 9m NS
Lebeau, 1993 (138) CPA-CCNU-ADR-VP16 aspirine induction 18 m all 303 285d 282d NS
Lebeau, 1994 (50) CPA-ADR-VP16-CCNU heparine SC induction 5 w all 277 261d 317d 0,01
Maurer, 1997 (139) ADR-CPA-VP16 warfarine induction 6 m LD 369 19m 21m NS
N: number; MS: median survival; S: significant; NS: non significant; m: month; w: week; d: days; ED: extensive disease; LD: limited disease; CT: 
chemotherapy; anti: anticoagulants/antiaggregants; VP16: etoposide; CPA: cyclophosphamide; ADR: adriamycin; MTX: methotrexate.
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